Belsomra (Suvorexant) Cost in New Hampshire: Prices, Insurance, and Savings in 2026

What Belsomra Actually Costs in New Hampshire

The gap between Belsomra's list price and what New Hampshire residents pay out of pocket is wide. Merck's wholesale acquisition cost (WAC) sits at $340 for a 30-day supply, but cash-pay pricing at New Hampshire retail pharmacies averages around $85 per month in 2026. That four-fold difference reflects negotiated rates, pharmacy benefit manager (PBM) contracts, and discount card availability.

Retail Pharmacy Variation

Prices vary by pharmacy. Independent pharmacies in smaller towns like Keene or Lebanon may quote differently than chains in Manchester or Nashua. Calling ahead or using a price-comparison tool before filling a prescription can save $20 to $40 on a single fill. The 10 mg tablet (the FDA-recommended starting dose for most adults) and the 20 mg tablet typically cost the same per unit, so dose escalation does not increase monthly spending at most pharmacies.

Why the List Price Rarely Applies

Few patients pay $340. That figure represents what wholesalers pay Merck before any rebates, discounts, or insurance negotiations take effect. Even uninsured patients can access the Merck savings card or pharmacy discount programs that bring costs closer to the $85 average. The list price matters mainly for calculating coinsurance percentages on some high-deductible health plans, where a patient might owe 20% to 30% of $340 ($68 to $102) before hitting their deductible 1.

New Hampshire Medicaid and Belsomra

New Hampshire Medicaid does not cover Belsomra as of 2026. The state's preferred drug list (PDL) for insomnia favors generic alternatives: trazodone, generic zolpidem, and generic eszopiclone all carry preferred status. Suvorexant, as a branded product without a generic equivalent, remains non-preferred and functionally excluded.

Prior Authorization Pathways

A prescriber can submit a prior authorization (PA) request arguing medical necessity. Approval requires documentation that the patient has tried and failed (or has a contraindication to) at least two preferred agents. Even with PA approval, coverage is not guaranteed. NH Medicaid's clinical review team evaluates requests individually, and denials can be appealed through the state's fair hearing process.

Practical Alternatives for Medicaid Patients

Patients on NH Medicaid who specifically need an orexin receptor antagonist may discuss lemborexant (Dayvigo) with their prescriber, though this agent also lacks preferred status in most state Medicaid programs. For patients whose insomnia responds to GABA-A modulators, generic zolpidem ER at roughly $10 to $25 per month is the lowest-cost covered option. A 2014 trial (N=254) comparing suvorexant to placebo found that suvorexant 20 mg reduced wake after sleep onset (WASO) by 22.7 minutes more than placebo at month 1, a clinically meaningful difference for patients who have not responded to older agents 2.

Insurance Coverage for Belsomra in New Hampshire

Most commercial insurance plans available in New Hampshire will cover Belsomra, but the path to coverage varies by carrier and tier placement.

Major Carriers

Anthem Blue Cross Blue Shield, Cigna, and Harvard Pilgrim (now part of Point32Health) all include suvorexant on their formularies in New Hampshire. Tier placement is typically Tier 3 (non-preferred brand), which means copays of $40 to $75 per month depending on the plan. Some plans place Belsomra on a specialty tier with coinsurance instead of a flat copay.

Ambetter (administered by Centene) plans sold on the NH Health Insurance Marketplace tend to require step therapy: documentation of failure on a generic sleep aid before Belsomra is approved. The step therapy requirement adds 2 to 4 weeks to the approval timeline.

Medicare Part D

Medicare Part D covers Belsomra. In 2026, after the Inflation Reduction Act's $2,000 annual out-of-pocket cap took full effect, Medicare beneficiaries filling Belsomra monthly will reach that cap faster than those on generics, but total annual exposure is capped regardless. Patients in the coverage gap previously faced significant costs for branded drugs; that gap has now closed under IRA provisions 3.

Self-Funded Employer Plans

Large employers in New Hampshire (Dartmouth Health, BAE Systems, Liberty Mutual's Keene operations) often self-fund their health plans. Formulary decisions for these plans are made by PBMs like Express Scripts, CVS Caremark, or OptumRx rather than by the insurer. Employees should check their specific plan formulary or call the number on their pharmacy benefit card.

The Merck Savings Card: How It Works in New Hampshire

Merck offers a manufacturer savings card for Belsomra that can reduce out-of-pocket costs to as low as $0 for eligible patients. The card works at every retail pharmacy in New Hampshire that accepts commercial insurance.

Eligibility Requirements

The card is available to patients with commercial insurance only. Medicare, Medicaid, Tricare, and other government-funded plan beneficiaries are ineligible by federal anti-kickback statute requirements. Patients must have a valid prescription and active commercial coverage. The card typically covers up to a set dollar amount per fill, with annual caps that vary by program year.

How to Activate

Patients can download the card from Merck's Belsomra website or receive one from their prescriber's office. The pharmacist processes the card as a secondary payer after running the primary insurance. If the primary insurance rejects the claim, some pharmacies can still process the savings card against the cash price. Not all pharmacy systems handle this automatically, so patients should ask the pharmacist to run both the insurance and the savings card.

Limitations

The savings card does not apply at mail-order pharmacies in all cases. Some PBMs restrict manufacturer copay card accumulation, meaning the card's value may not count toward the patient's deductible or out-of-pocket maximum. Anthem and Cigna plans in New Hampshire have adopted copay accumulator programs that use this restriction.

Compounded Suvorexant in New Hampshire

Compounded suvorexant is available in New Hampshire through licensed 503A compounding pharmacies. This is legal under both federal law (the Drug Quality and Security Act of 2013) and New Hampshire Board of Pharmacy regulations, provided the compounding pharmacy holds a valid NH state license and compounds pursuant to a patient-specific prescription.

What 503A Compounding Means

A 503A pharmacy compounds medications for individual patients based on prescriptions. Unlike 503B outsourcing facilities (which can produce larger batches without patient-specific prescriptions), 503A pharmacies operate under traditional state pharmacy law. In New Hampshire, several compounding pharmacies in the Concord, Manchester, and Seacoast regions offer compounded sleep aids.

Cost Considerations

Compounded formulations may cost less than the branded product, though pricing depends on the pharmacy, the specific formulation, and whether the compounder sources suvorexant API (active pharmaceutical ingredient) directly. Because suvorexant is still under patent protection until 2029, API sourcing for compounding exists in a legal gray area. Patients should confirm that their chosen pharmacy sources ingredients from FDA-registered suppliers.

Quality and Bioequivalence

Compounded medications are not FDA-approved and do not undergo the same bioequivalence testing as commercially manufactured tablets. The American Association of Clinical Endocrinology (AACE) and the Endocrine Society have noted in joint statements that compounded hormone preparations may vary in potency by 10% to 25% between batches 4. While those statements address compounded hormones specifically, the principle of batch-to-batch variability applies across compounded drug categories.

Telehealth Prescribing in New Hampshire

New Hampshire law permits telehealth prescribing of Belsomra. The state's telehealth parity law (RSA 415-J) requires insurers to cover telehealth visits at the same rate as in-person visits, and prescribers licensed in New Hampshire can prescribe Schedule IV controlled substances (suvorexant's DEA classification) via audio-video telehealth after establishing a patient-provider relationship.

DEA and State Requirements

Suvorexant is a Schedule IV controlled substance. Under the DEA's post-pandemic telehealth prescribing framework, prescribers can initiate Schedule III-V controlled substance prescriptions via telehealth if they conduct an audio-video evaluation and comply with state-specific rules. New Hampshire does not impose additional restrictions beyond the federal framework for Schedule IV drugs 5.

Telehealth Platforms Serving New Hampshire

Several telehealth platforms prescribe Belsomra to New Hampshire residents, including HealthRX, Cerebral, Done, and various sleep-specialty telehealth services. Appointment costs range from $0 (for insured visits with telehealth parity coverage) to $99 to $199 for cash-pay consultations. The prescription itself still needs to be filled at a pharmacy, so the total cost is the telehealth visit fee plus the medication cost.

How Suvorexant Compares to Other Insomnia Drugs on Cost

Belsomra is not the cheapest insomnia medication. It is not the most expensive either. Context matters.

Generic Alternatives

Generic zolpidem (Ambien) costs $5 to $15 per month. Generic eszopiclone (Lunesta) runs $10 to $30. Generic trazodone, used off-label for insomnia, is often under $10. These prices make older agents 4 to 17 times cheaper than Belsomra at cash-pay rates.

Other Orexin Receptor Antagonists

Lemborexant (Dayvigo), the other FDA-approved DORA, has a list price comparable to Belsomra and similar insurance coverage patterns. In the Herring et al. Key trial, suvorexant at doses of 40 mg and 20 mg demonstrated statistically significant improvements in both subjective total sleep time (sTST) and WASO compared to placebo over 4 weeks (P<0.001 for both endpoints) 2. Head-to-head data between suvorexant and lemborexant are limited, so cost and insurance coverage often drive the choice between them.

When the Price Difference Is Worth It

The clinical rationale for choosing suvorexant over cheaper generics typically involves one of three scenarios: the patient has failed or cannot tolerate GABA-A modulators, the patient has a history of complex sleep behaviors on zolpidem (a boxed warning concern), or the patient has comorbid substance use disorder where a non-GABA mechanism is preferred. The FDA's 2019 boxed warning update for zolpidem, eszopiclone, and zaleplon regarding complex sleep behaviors (sleepwalking, sleep-driving) does not apply to the DORA class 1.

Dr. Andrew Krystal, a sleep medicine researcher at UCSF, has noted: "Orexin receptor antagonists represent a mechanistically distinct approach to insomnia. For patients who experience parasomnias or next-day sedation with benzodiazepine receptor agonists, DORAs offer a viable alternative with a different side-effect profile" 6.

Discount Programs Beyond the Merck Card

New Hampshire residents have several additional avenues for reducing Belsomra costs.

Pharmacy Discount Cards

GoodRx, RxSaver, and SingleCare all list Belsomra pricing at New Hampshire pharmacies. These cards are free, require no insurance, and can be used at chains like CVS, Walgreens, Rite Aid, and Walmart. Prices through these platforms typically fall between $70 and $100 for a 30-day supply, depending on the pharmacy and the specific card.

Patient Assistance Programs

Merck's patient assistance program (Merck Helps) provides free Belsomra to uninsured patients who meet income eligibility criteria (generally at or below 400% of the federal poverty level). Applications require proof of income and a valid prescription. Processing takes 4 to 6 weeks, and approvals cover 12 months of medication.

340B Pharmacies

Federally qualified health centers (FQHCs) in New Hampshire, including Ammonoosuc Community Health Services, Lamprey Health Care, and Manchester Community Health Center, participate in the 340B Drug Pricing Program. Patients seen at these centers may access Belsomra at significantly reduced prices through their in-house or contract pharmacies. The 340B price for Belsomra is not publicly disclosed but is typically 25% to 50% below WAC.

New Hampshire-Specific Regulatory Considerations

New Hampshire's pharmaceutical regulatory environment affects Belsomra access in several ways.

No State Pharmaceutical Assistance Program

Unlike neighboring states (Maine's Drugs for the Elderly program, Vermont's VPharm), New Hampshire does not operate a state pharmaceutical assistance program for residents who fall into coverage gaps. This means uninsured or underinsured New Hampshire residents must rely on manufacturer programs, discount cards, or 340B pricing rather than state-funded subsidies.

Prescription Drug Monitoring Program

New Hampshire's Prescription Drug Monitoring Program (PDMP) tracks all Schedule II-V prescriptions, including suvorexant. Prescribers must check the PDMP before writing a new Belsomra prescription or refilling one for the first time. This does not affect cost but can affect access speed: a prescriber who identifies concerning patterns in the PDMP may decline to prescribe or may require additional clinical evaluation before writing the prescription.

According to the CDC's clinical practice guideline for prescribing controlled substances, PDMP checks serve as a safety measure rather than a barrier to appropriate treatment, and should not deter clinicians from prescribing indicated medications when the clinical benefit outweighs the risk 7.